Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:36:13 2024-05-17 am EDT			After market 12:26:43 pm
44.3 ^EUR	0.00%		44.15	-0.34%

Apr. 25	Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	MT

Formycon AG Appoints Stefan Glombitza as COO

November 16, 2017 at 02:00 am EST

Formycon AG appointed Stefan Glombitza as COO. Dr. Stefan Glombitza joined the company Management Board in October 2016 being in charge of the company operational development. His position on the Management Board continues until September 30, 2021.

Latest news about Formycon AG

Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ
Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia	Mar. 11	MT
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million	Jan. 30	MT
EU Medicines Regulator Accepts Formycon's Marketing Authorization Application for Eylea Biosimilar	Dec. 27	MT
Formycon JV Wins Canadian Approval for Retinal Diseases Treatment Ranopto	Dec. 07	MT
Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. Announces Health Canada Approves FYB201/Ranopto (Ranibizumab)	Dec. 07	CI
US FDA Accepts for Review Formycon, Fresenius' Biologics License Application for Stelara Biosimilar	Nov. 30	MT
Novartis AG : Sandoz takes its first steps on the stock exchange	23-10-04
EU Medicines Regulator Accepts Marketing Authorization Application for Formycon's Biosimilar Candidate	23-09-29	MT
Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
US FDA Accepts Formycon's Biologics License Application for Eylea Biosimilar	23-08-29	MT
Formycon, Fresenius to Launch Biosimilar for Johnson & Johnson's Anti-inflammatory Drug by 2025	23-08-07	MT
Certain Shares of Formycon AG are subject to a Lock-Up Agreement Ending on 2-AUG-2023.	23-08-01	CI
Formycon Announces Submission of the Biologics License Application for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration	23-06-29	CI
Jefferies starts Formycon with 'Buy' - Target 101 euros	23-05-22	DP
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Formycon AG Provides Earnings Guidance for the Year 2023	23-04-27	CI
Formycon Concludes Clinical Development of Stelara Biosimilar; Regulatory Filings Expected in Q3	23-04-25	MT
Formycon AG Announces Successful Results of Phase I Clinical Trial for Ustekinumab Biosimilar Candidate FYB202 and Concludes Clinical Development	23-04-25	CI
Formycon's Interim Analysis of Late-stage Trial of Aflibercept Biosimilar Candidate Shows Efficacy Against Macular Degeneration	23-02-06	MT
Formycon Raises EUR70 Million to Fund Biosimilar Candidates' Development	23-02-02	MT
Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit	23-02-02	MT
Strong Demand Prompts Formycon to Boost Size of Capital Increase	23-02-02	MT

Chart Formycon AG

Duration

Period

More charts

Company Profile

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Berenberg European Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Formycon AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.3 EUR

Average target price

86 EUR

Spread / Average Target

+94.13%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FORMYCON AG	-21.45%	850M
MODERNA, INC.	+34.48%	50.85B
IQVIA HOLDINGS INC.	+0.65%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.89%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.61%	19.13B
BIO-TECHNE CORPORATION	+8.63%	13.05B
MEDPACE HOLDINGS, INC.	+27.24%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.49%	12.08B

Other Biotechnology & Medical Research